Juengling FD Allenbach G Bruehlmeier M Klaeser B Wissmeyer MP Garibotto V Felbecker A Georgescu D 2020 While FDG-PET imaging of the brain for the differential diagnosis of dementia has been covered by the compulsory health insurance in Switzerland for more than a decade, beta-amyloid-PET just recently has been added to the catalogue of procedures that have been cleared for routine use, provided that a set of appropriate use criteria (AUC) be followed. To provide guidance to dementia care practitioners, the Swiss Society of Nuclear Medicine and the Swiss Memory Clinics jointly report a mini-review on beta-amyloid-PET and discuss the AUC set into effect by the Swiss Federal Office of Public Health, as well as their application and limitations. https://sonar.ch/global/documents/236053 eng info:eu-repo/semantics/altIdentifier/doi/10.1055/a-1277-6014 info:eu-repo/semantics/altIdentifier/pmid/33080626 Nuklearmedizin. Nuclear medicine. - 2020 Radiology Nuclear Medicine and imaging General Medicine Appropriate use criteria for dementia amyloid imaging in Switzerland - mini-review and statement on behalf of the Swiss Society of Nuclear Medicine and the Swiss Memory Clinics. http://purl.org/coar/resource_type/c_6501